In this study we show for the first time, the therapeutic potential of apoptin-derived decapeptide for the treatment of CML by establishing the minimal region of apoptin interaction domain with BCR-ABL1. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.